Studio di fase II con docetaxel in pazienti con sarcoma dei tessuti molli in fase avanzata

Clinica Terapeutica

Volumn 149, Issue 2, 1998, Pages 121-125

  Amodio, A ^a,b   Carpano, S ^a   Paoletti, G ^a   Gionfra, T ^a   Rinaldi, M ^a   Manfredi, C ^a   Foggi, P ^a   Lopez, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b II Div Med   (Italy)

Author keywords

Chemotherapy; Docetaxel; Soft tissue sarcomas

Indexed keywords

DOCETAXEL; PREDNISONE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; SOFT TISSUE SARCOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; FIBROSARCOMA; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; LEIOMYOSARCOMA; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; PREDNISONE; PREMEDICATION; SARCOMA; TAXOIDS; THROMBOCYTOPENIA;

EID: 0031869595     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Benjamin RS, Wiernik PH, Bachur NR: Adriamycin chemotherapy: Efficacy, safety and pharmacologic basis of an intermittent single-dosage schedule. Cancer 33:19-27, 1974
2. Omura GA, Major FJ, Blessing JA, et al: A randomized study of adriamycin with or without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52:626-632, 1983
3. Schoenfeld D, Rosembaum C, Horton J, et al: A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide for advanced sarcoma. Cancer 50:2757-2762, 1982
4. Borden EC, Amaro DA, Rosenbaum C, et al: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcoma. J Clin Oncol 5:840-850, 1987
5. Borden EC, Amato DA, Edmonson JH, et al: Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft tissue sarcomas. Cancer 66:862-867, 1990
6. Mouridsen HT, Bastholt L, Somers R, et al: Adriamycin versus epiadriamycin in advanced soft tissue sarcomas. A randomized phase II/III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 23:1477-1483, 1987
7. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1539-1545, 1995
8. Edmonson JH, Ryan LM, Blum RH, et al: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin alone versus ifosfamide plus doxorubicin or mitomyicin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11:1269-1275, 1993
9. O'Bryan RM, Baker LH; Gottlieb JE, et al: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940-1948, 1977
10. O'Bryan RM, Luce JK, Talley RW, et al: Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1-8, 1973
11. Benjamin RS, Legha SS, Patel SR, et al: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The MD Anderson experience. Cancer Chemother Pharmacol 31:S174-S179, 1993 (suppl 2)
12. Le Cesne A, Antoine E, Speilmann M, et al: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13: 1660, 1995
13. Scheulen ME, Niederle N, Bremer K, et al: Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: Results of a clinical phase II-study with 151 patients. Cancer Treat Rev 10:93-101, 1983 (suppl A)
14. Elias AD, Eder JP, Shea T, et al: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 8: 170-178, 1990
15. Stuart-Harris R, Harper PG, Kaye SB, et al: High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 10:163-164, 1983 (suppl A)
16. Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft tissue sarcomas: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 31:S180, 1993 (suppl 2)
17. Antman KH, Ryan L, Elias A, et al: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7: 126-131, 1989
18. Lavelle F, Fizames C, Gueritte-Voegelin F et al: Experimental properties of RP 56976, a taxol derivative. Proc Am Assoc Cancer Res 30:566, 1989
19. Bissery MC, Bayssas M, Lavelle F: Preclinical evaluation of intravenous taxotere (RP 56976, NSC 628503) a taxol analog. Proc Am Assoc Cancer Res 31:417, 1990
20. Van Hoesel QG, Verweij J, Catimel G, et al: Phase II Study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5:539-542, 1994
21. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 47:207-214, 1981
22. Kaplan EI, Meier P: Nonparametric estimation from incomplete estimations. J Am Slat Assoc 53: 457, 1958
23. De Metri GD: High dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Sem Oncol 23:22-26, 1996 (suppl 6)
24. Antman KH, Crowley J, Balcerzak S, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
25. Patel SR, Vadhan-Ray S, Burgess MA, et al: Dose-intensive chemotherapy in soft tissue sarcomas. Proc Am Soc Clin Oncol 15:1681, 1996
26. Keohan ML, Taub RN: Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Sem Oncol 24(5): 572-579, 1997
27. Vanhoefer U, Cao S, Harstrick A, et al: Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 8:1221-1228, 1997
28. Verweij J, Judson I, Crowther D, et al: Randomized study comparing docetaxel (Taxotere) to doxorubicin in previously untreated soft tissue sarcomas. Proc Am Soc Clin Oncol 16:496a, 1997 (abstr 1788)
29. Edmonson JH, Ebbert LP, Nascimento AG, et al: Phase II study of docetaxel in advanced soft tissue sarcomas. Am J Clin Oncol 19(6): 574-576, 1996
30. Verusio C, Romanini A, Frustaci S, et al: Phase II study with docetaxel (Taxotere) as second line treatment of advanced soft tissue sarcomas in adult. Eur J Cancer 31A(S5): S114 (abstr 507)